Bonded hemoglobin nanoparticles patented

Business News Agency Aug. 3th Recently, researchers of the Research Group of Prof. Huang Yubin of the Changchun Institute of Applied Chemistry of the Chinese Academy of Sciences and the research team of the Jing-bin Bin team have combined self-assembling technology with the idea of ​​macromolecular bonding drugs to prepare a kind of red blood cell The product's bonded hemoglobin nanoparticles were patented and approved. The study provides a new way of thinking for the study of contemporary blood substitutes. The clinical application of blood substitutes is a great boost.

Blood plays an indispensable role in maintaining normal life. In the process of clinical blood transfusion, there are many disadvantages of human blood, such as: cross blood test matching, time-consuming and cost-effective; short storage time, 3 to 6 weeks; the emergence of various blood-borne diseases and so on. From the concept of blood substitutes, researchers have developed many different types of blood substitutes, especially hemoglobin-based artificial oxygen carriers. However, nanoparticles of such blood substitutes generally have small particle size, short circulation time in the body, easy entry into the vascular endothelium, and vasorelaxation affecting factor NO binding leads to vasoconstriction, hypertension, and decreased blood flow at microcirculatory levels. And tissue oxidation and other side effects.

Researchers Huang Yubin and Jing Shengbin proposed this method by combining biodegradable amphiphilic block polymers as a carrier and combining the hemoglobin molecules with amphiphilic polymer self-assembly through chemical bonding. The obtained hemoglobin nanoparticle can obtain a desired particle size by adjusting the ratio of the block copolymer, avoiding various defects due to the small particle size. At the same time, the attachment of chemical bonds also greatly improves the stability of hemoglobin in the blood circulation.